Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease
- 1 January 2002
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 122 (1), 7-14
- https://doi.org/10.1053/gast.2002.30770
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitisGut, 2002
- A frameshift mutation in NOD2 associated with susceptibility to Crohn's diseaseNature, 2001
- Differential activity and expression of mitogen-activated protein kinases in inflammatory bowel diseaseGastroenterology, 2001
- Review article: targeting TNFα as a key cytokine in the inflammatory processes of Crohn’s disease — the mechanisms of action of infliximabAlimentary Pharmacology & Therapeutics, 1999
- Role of Interleukin (IL)-2 Receptor β-Chain Subdomains and Shc in p38 Mitogen-activated Protein (MAP) Kinase and p54 MAP Kinase (Stress-activated Protein Kinase/c-Jun N-terminal Kinase) ActivationPublished by Elsevier ,1999
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency.Proceedings of the National Academy of Sciences, 1996
- Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone.The Journal of Experimental Medicine, 1996
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995
- Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).Gut, 1989